<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972189</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-B3101-II-01</org_study_id>
    <nct_id>NCT03972189</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Phase II, Open Label, Single Arm Study of the Efficacy and Safety of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess efficacy and safety of oral TQ-B3101 administered to patients with Advanced
      Non-Small Cell Lung Cancer (NSCLC) that confirmed ROS1 positive gene mutation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to approximately 20 months</time_frame>
    <description>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to approximately 20 months</time_frame>
    <description>DOR was defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to approximately 20 months</time_frame>
    <description>Percentage of Participants Achieving Complete Response (CR) and Partial Response (PR) and Stable Disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to approximately 20 months</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to approximately 24 months</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>ROS1-positive Non-Small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>TQ-B3101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-B3101</intervention_name>
    <description>TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.</description>
    <arm_group_label>TQ-B3101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.18 years and older. 2.Eastern Cooperative Oncology Group (ECOG) performance status of 0
        to 1；Life expectancy ≥ 3 months.

        3.Understood and Signed an informed consent form. 4.Histologically or cytologically
        confirmed locally advanced or metastatic NSCLC .

        5.Subjects in the screening period should provide a written report of ROS1 positive, or
        tumor histological specimens obtained at the time of diagnosis/post before enrollment are
        sent to the central laboratory to confirm ROS1 positive.

        6. Had received no more than two chemotherapy regimens. 7.At least 1 measurable tumor
        lesion other than brain lesions within 28 days before first dose based on RECIST 1.1.

        8.The main organs function are normally, the following criteria are met:

          1. routine blood tests（no blood transfusion and blood products within 14
             days）：hemoglobin（Hb）≥90g/L；absolute neutrophil count（ANC）≥1.5×109/L；
             platelets（PLT）≥100×109/L.

          2. Blood biochemical examination: alanine transaminase（ALT）and aspartate
             aminotransferase（AST）≤2.5×upper limit of normal (ULN)（when the liver is invaded, ALT,
             and AST ≤5× upper limit of normal (ULN) ）； total bilirubin (TBIL)≤1.5×upper limit of
             normal (ULN)；Serum creatinine ≤ 1.5 × upper limit of normal (ULN); or creatinine
             clearance calculated ≥ 50ml / min (calculated according to Cockcroft-Gault formula);

          3. left ventricular ejection fraction (LVEF) measured by the Cardiac echocardiography ≥
             50%.

             9.Women must meet one of the following conditions:has undergone surgical
             sterilization;have been menopausal at least 1 year;have fertility, the following
             conditions must be met;Serum pregnancy test results were negative; throughout the
             study period to 6 months after the last dose, agreed to adopt an approved method of
             contraception (for example: oral contraception, injection contraception or implanted,
             barrier-effect Contraceptive methods, spermicides and condoms, or intrauterine
             devices).Men must meet one of the following conditions:has surgical sterilization;an
             approved method of contraception must be used throughout the study period and 6 months
             after the last dose.

             Exclusion Criteria:

               1. Has any known endothelial growth factor receptor (EGFR) positive mutation.

               2. Prior therapy with crizotinib, anti-programmed cell death (PD)-1, anti-PD-L1 or
                  any other ROS1 inhibitor.

               3. Has multiple factors affecting oral medication, such as inability to swallow,
                  post-gastrointestinal resection, chronic diarrhea and intestinal obstruction,
                  etc.

               4. Has diagnosed and/or treated additional malignancy within 5 years prior to
                  randomization with the exception of cured carcinoma in situ of the cervix、
                  non-melanoma skin cancers and superficial bladder tumors.

               5. Has a history of hypertensive crisis, hypertensive encephalopathy; or
                  uncontrolled hypertension.

               6. Has clinically significant, uncontrolled cardio-cerebral vascular disease.

               7. Has major surgery and anti-tumor treatment before two weeks of treatment and
                  participated in other drug clinical trials within four weeks.

               8. Has known central nervous system metastasis and/or spinal cord compression,
                  cancerous meningitis, and pia mater disease.

               9. Has in screening period confirmed HCV positive, HIV positive, active syphilis
                  positive, or HBsAg positive, HBV DNA titers &gt;500 copies/ml and stable time &lt;14
                  days after symptomatic treatment,or has a history of stem cells and organ
                  transplantation.

              10. Has history of psychotropic substance abuse that unable to abstain from or mental
                  disorder.

              11. According to the judgement of the researchers, there are other factors that may
                  lead to the termination of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shun Lu, Doctor</last_name>
    <phone>021-22200000*3121</phone>
    <email>shun-lu@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui chest hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuhong Min, Doctor</last_name>
      <email>1320722827@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi Hu, Doctor</last_name>
      <email>huyi0401@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tumor hospital, Chinese academy of medical sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan Wang, Doctor</last_name>
      <email>wangyanyifu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Fang, Doctor</last_name>
      <email>fangjian5555@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Tumor Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wu Zhuang, Doctor</last_name>
      <email>zhuangwu2008@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated tumor hospital of sun yat-sen university</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuyu Cai, Doctor</last_name>
      <email>caixy@sysucc.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of guangdong pharmaceutical university</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xicheng Wang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of guangzhou medical college</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianxing He, Doctor</last_name>
      <phone>020-83062902</phone>
      <email>Hejx@vip.163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated tumor hospital of Harbin medical university</name>
      <address>
        <city>Ha'erbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Yu, Doctor</last_name>
      <email>gpyuyan@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shundong Cang, Doctor</last_name>
      <email>cangshundong@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Tumor Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhiyong Ma, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan provincial tumor hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Wu, Doctor</last_name>
      <email>wulin-calf@vip.163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Centre-south University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huaping Yang, Doctor</last_name>
      <email>lyhuaping@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second hospital of jilin university</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Zhang, Doctor</last_name>
      <email>doctorzhangj@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital of dalian medical university</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Zhang, Doctor</last_name>
      <email>zydl@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiuwen Wang, Doctor</last_name>
      <email>wangxiuwen@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linyi tumor hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianhua Shi, Doctor</last_name>
      <email>lyzlyygcp@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qingdao University Medical College Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhuang Yu, Doctor</last_name>
      <email>yuzhang2002@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiaotong University Affiliated Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shun Lu, doctor</last_name>
      <phone>021-22200000*3121</phone>
      <email>shun-lu@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of xi 'an jiaotong university</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Yao, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin tumor hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kai Li, Doctor</last_name>
      <email>likai_fnk@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital School of Medical,Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongming Pan, Doctor</last_name>
      <phone>057186006926</phone>
      <email>shonco@sina.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

